Prolia Efficacy Data

Fracture incidence and BMD data

Fracture Risk Reduction

Down arrow

Fracture incidence with Prolia treatment over 10 years in postmenopausal osteoporosis1

Spine Icon

New vertebral fractures

Prolia

placebo

Vertebral Fracture Chart
Hip Fracture Icon

Hip fractures

Prolia

placebo

Hip Fracture Chart
Nonvertebral Fracture Risk Reduction Icon

Non-vertebral fractures

Prolia

placebo

Nonvertebral Fracture Chart

BMD data with Prolia treatment over 10 years in postmenopausal osteoporosis1

Spine Icon

Lumbar spine BMD

Bone Mineral Density

Lumbar Spine Chart
Pelvis Bone Icon

Total hip BMD

Bone Mineral Density

Total Hip Chart
Femoral Neck Icon

Femoral neck BMD

Bone Mineral Density

Femoral Neck Chart

ARR=absolute risk reduction; BMD=bone mineral density; FRR=fracture risk reduction; RRR=relative risk reduction
A randomized, double-blind, placebo-controlled study in postmenopausal patients with osteoporosis receiving 60 mg Prolia (n=3,902) or placebo (n=3,906) subcutaneously once every 6 months for 3 years. Subjects were between the ages of 60 and 91 years and had bone mineral density (BMD) T-scores < -2.5 and ≥ -4.0. All women received at least 1000 mg calcium and at least 400 IU vitamin D supplementation per day. 1
* Annualized yearly subject incidence.
In women who received Prolia in the 3-year placebo-controlled phase and continued on therapy in the long-term, open-label extension.

Additional Resources

FREEDOM Clinical Trial Icon
FREEDOM Clinical Trial

Access the FREEDOM trial in the virtual library.

Virtual LibraryArrow Image
Product Monograph Icon
Product Monograph

Download the Prolia Product Monograph in the virtual library.

Virtual LibraryArrow Image
References

You are now leaving the Prolia.ca website.

The linked sites are not under the control of Amgen, and Amgen is not responsible for the content available on the linked sites. Such links do not imply Amgen's endorsement of material on any other site, and Amgen disclaims all liability with regard to your access to such linked websites. Amgen provides links to other Internet sites as a convenience to users, and access to such linked sites is at your own risk.

Do you want to link to our other external sites and leave Prolia.ca?

You are now leaving the Prolia.ca website. Please note that the information you are about to view may not comply with Canadian regulatory requirements. Marketing authorizations and availability of products may differ between Canada and other countries.

Proceed